

Figure 1. C4-V3 Th-CTL Peptides Induce HLA B7 Reactive CD8+ CTL in Normal HIV-1 Seronegative Humans. Panels A a C show specific lysis from in vivo immunization and in vitro restimulation against each of the V3 B7 CTL epitope variants. BLCL-lymphoblastoid cell line (BCLC) no peptide coating control. C4=C4 Th determinant peptide on BCLC, V3MN, V3RF, V3EV91, at V3Can0A are the B7 CTL epitope variant peptide coated on BCLC. Data show patient in Panel A responded to 1 of 4 B7 CTL epitope variants (the HIV EV91 variant) while the patient in Panel C responded to 3 of 4 B7 epitope variants (HIVMN, EV91 and Can0). Panels B and D show 2 HLA B7 negative individuals that made no CTL response to the B7-restricted CTL peptide immunogen after both in in vivo immunization and in vitro restimulation.